Novocure (NVCR) analyst forecast and price target
Analyst forecast
Consensus of 7 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Wedbush | Maintained | Neutral | $20.00 from $18.00 | Jul 24, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $52.00 from $46.00 | Jul 23, 2026 |
| JP Morgan | Maintained | Neutral | $17.00 | Jul 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $46.00 from $48.00 | Jun 18, 2026 |
| Wells Fargo | Maintained | Equal-Weight | $17.00 from $13.50 | May 4, 2026 |
| Evercore ISI Group | Maintained | Outperform | $20.00 from $16.00 | May 1, 2026 |
| Wedbush | Maintained | Neutral | $18.00 | Apr 16, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $49.00 from $47.00 | Feb 26, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $47.00 from $39.00 | Feb 12, 2026 |
| Wedbush | Maintained | Neutral | $18.00 | Jan 15, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $39.00 from $42.00 | Jan 13, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $42.00 from $38.00 | Oct 30, 2025 |
| JP Morgan | Maintained | Neutral | $23.00 from $25.00 | Oct 27, 2025 |
| Wells Fargo | Downgraded | Overweight → Equal-Weight | $14.50 from $40.00 | Jul 25, 2025 |
| Ladenburg Thalmann | Initiated Coverage | Buy | $30.00 | Jul 8, 2025 |
| Piper Sandler | Maintained | Overweight | $34.00 | Jun 27, 2025 |
| Piper Sandler | Maintained | Overweight | $34.00 from $42.00 | Apr 23, 2025 |
| Wedbush | Maintained | Neutral | $27.00 from $29.00 | Apr 16, 2025 |
| JP Morgan | Maintained | Neutral | $28.00 from $29.00 | Apr 10, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $38.00 | Jan 14, 2025 |
Frequently asked questions
What is the price target for NVCR stock?
The average 12-month analyst price target for Novocure (NVCR) is $29.67, with a high estimate of $52.00 and a low of $17.00, across 3 analysts.
Is NVCR a buy, sell, or hold?
Analysts covering Novocure currently average a Buy rating: 4 buy, 3 hold and 0 sell, from 7 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for NVCR?
The average price target of $29.67 implies 67.18% upside from the last price of $17.75.
What is the latest analyst rating on NVCR?
On Jul 24, 2026, Wedbush maintained Novocure at Neutral with a price target of $20.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.